ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
01 Mar 2024 11:10

Hong Kong Buybacks Weekly (Mar 1st): AIA, Kuaishou Technology, Swire Pacific

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Logo
444 Views
Share
bullishCGN Power
01 Mar 2024 06:10

FXI Rebalance: Three Buys. Three Sells

There are 3 buys, 3 sells for the FXI in March. Two stocks have over 1x ADV to buy and cumulative excess volume has increased on all stocks. Trades...

Logo
391 Views
Share
25 Feb 2024 05:50

Index Rebalance & ETF Flow Recap: HSCEI, HSCI, HSTECH, HSIII, STTF, Top50, Div+, FXI, FnGuide

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
603 Views
Share
bullishLi Auto
25 Feb 2024 05:05

HK Connect SOUTHBOUND Flows (To 23 Feb 2024); Selling of Consumer Stocks, But Big Buys of SOEs

SOUTHBOUND saw significant net buying in the first week after Chinese New Year. Large caps and SOEs were heavily bought. Especially in energy and...

Logo
398 Views
Share
x